Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes

医学 肿瘤科 乳腺癌 内科学 妇科 癌症
作者
Linxiaoxi Ma,Benlong Yang,Jiong Wu
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:129: 102770-102770
标识
DOI:10.1016/j.ctrv.2024.102770
摘要

Breast cancer diagnosed in premenopausal women tends to be more aggressive and the benefit of ovarian function suppression (OFS), at least in certain groups of patients, is well known. There is hesitancy in using OFS in some groups of patients who may otherwise benefit from the treatment. For instance, it is clear that in premenopausal patients with hormone receptor-positive (HR + ), high-risk, early-stage breast cancer, gonadotropin-releasing hormone agonists (GnRHa) should be given in the adjuvant setting; however, confusion remains whether premenopausal patients with intermediate-risk disease benefit from GnRHa, given the lack of consensus on its definition in guidelines and clinical practice. Most recent evidence on the long-term efficacy of GnRHa, with up to 20-years of follow-up, reinforced its benefits in premenopausal patients with early-stage breast cancer. In this comprehensive review, we reviewed the long-term efficacy in terms of improvement in DFS and OS for early-stage HR + breast cancer and examined evidence from multiple randomized clinical studies to identify the clinicopathological characteristics that correlated with improved disease-free survival (DFS) and overall survival with the addition of OFS to adjuvant endocrine therapy. Other aspects of GnRHa, including its efficacy in advanced breast cancer, safety profile, evidence in ovarian function preservation, and the advantages of long-acting formulations were also discussed. By addressing the existing gaps and grey areas regarding the inclusion of OFS as a crucial treatment component for premenopausal breast cancer patients, physicians are more aware of who to administer and the potential impact on survival outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
林宸轩完成签到,获得积分10
刚刚
Orange的应助被逢坂大河采纳,获得10
刚刚
meshia发布了新的文献求助10
刚刚
天天快乐的应助被影逐光采纳,获得10
刚刚
1秒前
所所的应助被XxX采纳,获得10
1秒前
上官若男的应助被宁灭龙采纳,获得10
1秒前
1秒前
lee完成签到,获得积分10
2秒前
aidenchen完成签到,获得积分10
2秒前
2秒前
2秒前
王珏完成签到,获得积分10
3秒前
4秒前
深情安青的应助被小白采纳,获得10
4秒前
CaliU发布了新的文献求助10
4秒前
搜集达人的应助被Daangxi采纳,获得10
4秒前
lk发布了新的文献求助10
5秒前
所所的应助被困就睡觉采纳,获得10
5秒前
lyhh完成签到,获得积分10
5秒前
5秒前
英姑的应助被忧郁的鱿鱼采纳,获得10
5秒前
风趣的鼠标完成签到,获得积分10
6秒前
Color完成签到,获得积分10
6秒前
甜甜发布了新的文献求助10
6秒前
FashionBoy的应助被yy采纳,获得10
7秒前
墨辞完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
可爱觅松发布了新的文献求助10
7秒前
7秒前
田様的应助被明理鸿采纳,获得10
7秒前
秋风的应助被wyk采纳,获得10
7秒前
杀出个黎明举报求助违规成功
8秒前
Anonymous举报求助违规成功
8秒前
MchemG举报求助违规成功
8秒前
Ren的应助被朋友需要采纳,获得200
8秒前
脑洞疼的应助被lulululu采纳,获得10
8秒前
扶风阁主发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949